Cytopenia is an indication for drug development with over 90 pipeline drugs currently active. According to GlobalData, preregistered drugs for Cytopenia have a 94.12% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Cytopenia compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Likelihood of Approval Analysis for Cytopenia

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cytopenia overview

Cytopenia is characterized by a reduction in blood cell numbers, encompassing red and white blood cells and platelets. Various factors, including bone marrow disorders, autoimmune conditions, infections, or certain medications, can contribute to this condition. Aplastic anemia, a specific type of cytopenia, results from a significant reduction in all blood cell types due to bone marrow failure. Neutropenia, involving a low white blood cell count, and thrombocytopenia, characterized by a low platelet count, carry specific risks like increased infection susceptibility or bleeding tendencies. Diagnosis relies on blood tests and bone marrow examinations, guiding appropriate treatment strategies. Management strategies include addressing underlying causes, blood transfusions, or, in severe cases, bone marrow transplantation. Regular medical monitoring is crucial for effective cytopenia management and to prevent associated complications.

For a complete picture of PTSR and LoA scores for drugs in Cytopenia, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.